EyePoint Pharmaceuticals appointed John Landis, PhD, to its board of directors.
Here are four highlights:
1. Dr. Landis brings more than 30 years of pharmaceutical research and development experience to the position.
2. He will serve on the board's science committee.
3. Dr. Landis was most recently Bioanalytical Systems' board chairman.
4. EyePoint is planning the commercial launches of two ophthalmic products in 2019.
"I look forward to guiding the company as it executes on its strategic and commercial corporate goals in support of the transition to a commercial-stage specialty pharmaceutical company with a pipeline of innovative products for ocular diseases," Dr. Landis said.